National Institutes of Health
Bethesda, MD
Accepting patients
Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
- Donor Lymphocyte Infusion (DLI)
- Post-Allogeneic Stem Cell Transplant
- Phase 1/2
Not currently accepting
Mirdametinib and Sirolimus
A Phase 1b/2 Study of Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (RRMM)
- MEK Inhibitor
- Phase 1/2
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
Accepting patients
Autologous T-Cells
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- T Cell
- Adoptive Cellular Therapy
- Phase 2
Accepting patients
Autologous T Cells
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
- T Cell
- Phase 1
1 hidden based on your filters.Show All